PAVmed Q2 2026 Earnings Report

PAVmed EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.63
• Beat/Miss: N/A
• One Year Ago EPS: N/A

PAVmed Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $0.05 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

PAVmed Announcement Details

• Quarter: Q2 2026
• Date: 8/14/2026
• Time: Before Market Opens
• Conference Call Date: Friday, August 14, 2026
• Conference Call Time: 8:30AM ET

PAVmed (NASDAQ:PAVM) is a clinical-stage medical technology company focused on acquiring, developing and commercializing innovative medical devices aimed primarily at gastrointestinal endoscopy and related therapeutic areas. Its portfolio includes FDA-cleared products such as EsoFLIP® Distensibility System for the treatment of esophageal strictures and MUSE™ (Medigus Ultrasonic Surgical Endostapler) for endoscopic fundoplication in gastroesophageal reflux disease (GERD). In addition to its gastrointestinal franchise, PAVmed is advancing early-stage programs targeting indications in oncology, urology and dermatology.

Founded in 2012, PAVmed has built its pipeline through internal research and development as well as strategic collaborations and acquisitions. The company completed its initial public offering in 2017 and maintains research, development and regulatory operations in North America and strategic partnerships in Europe. PAVmed’s multidisciplinary team leverages clinical insights, engineering expertise and regulatory know-how to shepherd devices from concept through pivotal studies and commercialization.

PAVmed’s executive leadership brings together seasoned professionals from the medical device, clinical practice and regulatory sectors. The management team emphasizes streamlined regulatory pathways and robust clinical trial design, seeking to deliver less-invasive treatment options that address high unmet needs. Though based in the United States, the company’s regulatory clearances and distribution agreements extend into key international markets.

Looking ahead, PAVmed is focused on driving commercial adoption of its approved devices while advancing its mid- and late-stage programs toward pivotal data readouts and regulatory submissions. By targeting areas where minimally invasive approaches can improve patient outcomes and reduce healthcare costs, the company aims to establish sustainable growth through a diversified pipeline of differentiated medical technologies.